scholarly journals Comparison of Central Nervous System Adverse Effects of Amantadine and Rimantadine Used as Sequential Prophylaxis of Influenza A in Elderly Nursing Home Patients

2000 ◽  
Vol 160 (10) ◽  
pp. 1485 ◽  
Author(s):  
Linda A. Keyser ◽  
Margaret Karl ◽  
Anne N. Nafziger ◽  
Joseph S. Bertino
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nursing Home ◽  
Adverse Effects ◽  
Influenza A ◽  
Nursing Home Patients

scholarly journals Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Hiroshi Kataoka ◽  
Daisuke Shimada ◽  
Hitoki Nanaura ◽  
Kazuma Sugie
Keyword(s):  
Central Nervous System ◽  
Cell Death ◽  
Nervous System ◽  
Monoclonal Antibodies ◽  
Programmed Cell Death ◽  
Adverse Effects ◽  
Neuromuscular Disorders ◽  
Neurological Complications ◽  
Programmed Cell Death 1 ◽  
The Central Nervous System

ABSTRACT This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only.

Probable Encephalopathy and Spasticity in a Multiple Sclerosis Patient Following Carbapenem Administration: A Case Report and Brief Literature Review

2021 ◽  
pp. 089719002110632
Author(s):  
Claire V Klimko ◽  
James M Sanders ◽  
Meagan L Johns
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Adverse Effect ◽  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Adverse Effects ◽  
Multiple Sclerosis Patient ◽  
Specific Patient ◽  
Appropriate Treatment

Purpose: The purpose of this case report is to describe spasticity and encephalopathy that developed in a multiple sclerosis patient following carbapenem administration. Summary: A 55-year-old female with multiple sclerosis developed spasticity and encephalopathy within 24 hours of meropenem and ertapenem administration. This was the second time that she had developed encephalopathy following carbapenem administration. The patient gradually recovered over four days following discontinuation of carbapenem therapy. Conclusion: Carbapenem neurotoxicity, a well-documented adverse effect, has been linked to several risk factors, including central nervous system lesions. Despite this, there is little evidence describing the risk of neurotoxicity in patients with multiple sclerosis. It is important to understand the potential adverse effects of carbapenems in specific patient populations to help guide appropriate treatment of infections.

Lanthanum chloride induces neuron damage by activating the nuclear factor-kappa B signaling pathway in activated microglia

Metallomics ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1277-1287 ◽  
Author(s):  
Licheng Yan ◽  
Jinghua Yang ◽  
Miao Yu ◽  
Yanxin Lu ◽  
Liling Huang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Rare Earth ◽  
Adverse Effects ◽  
Signaling Pathway ◽  
Earth Element ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Neuron Damage ◽  
The Central Nervous System

Lanthanum is a rare earth element which can have adverse effects on the central nervous system (CNS).

scholarly journals Central Nervous System Medication Burden and Risk of Recurrent Serious Falls and Hip Fractures in Veterans Affairs Nursing Home Residents

2018 ◽  
Vol 67 (1) ◽  
pp. 74-80 ◽  
Author(s):  
Sherrie L. Aspinall ◽  
Sydney P. Springer ◽  
Xinhua Zhao ◽  
Francesca E. Cunningham ◽  
Carolyn T. Thorpe ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nursing Home ◽  
Hip Fractures ◽  
Nursing Home Residents ◽  
Veterans Affairs

scholarly journals Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial

2019 ◽  
Vol 6 (7) ◽  
Author(s):  
Sirichai Wiriyatanakorn ◽  
Somnuek Sungkanuparph
Keyword(s):  
Central Nervous System ◽  
Randomized Controlled Trial ◽  
Nervous System ◽  
Adverse Effects ◽  
Viral Suppression ◽  
Controlled Trial ◽  
Virological Suppression ◽  
Randomized Controlled ◽  
Resource Limited ◽  
Limited Setting

AbstractA randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.

scholarly journals Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents

2017 ◽  
Vol 65 (6) ◽  
pp. 1183-1189 ◽  
Author(s):  
Joseph T. Hanlon ◽  
Xinhua Zhao ◽  
Jennifer G. Naples ◽  
Sherrie L. Aspinall ◽  
Subashan Perera ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nursing Home ◽  
Nursing Home Residents
Sign in / Sign up

Export Citation Format

Share Document